Clinical Trials
31 trialsNCT05784012 2026-06-04
RADIAN
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase 1/2 Active not recruiting
NCT05723562 2026-05-26
AZUR-1
GlaxoSmithKline
Phase 2 Active not recruiting
NCT05277051 2026-05-22
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Active not recruiting
NCT06062420 2026-05-22
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
GlaxoSmithKline
Phase 2 Active not recruiting
NCT04584255 2026-05-13
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04126200 2026-05-06
DREAMM 5
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT04701307 2026-04-22
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03680508 2026-04-02
TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer
University of Hawaii
Phase 2 Active not recruiting
NCT04387084 2026-03-23
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
University of Southern California
Phase 1 Active not recruiting
NCT04068753 2026-02-10
STAR
University of Oklahoma
Phase 2 Active not recruiting
NCT06879717 2026-01-16
PULMO-01
iOnctura
Phase 1/2 Active not recruiting
NCT02715284 2026-01-13
GARNET
Tesaro, Inc.
Phase 1 Active not recruiting
NCT06238635 2026-01-13
Dostarlimab and Cobolimab in Advanced Cervical Cancer
Beth Israel Deaconess Medical Center
Phase 2 Active not recruiting
NCT04673448 2026-01-09
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
Phase 1 Active not recruiting
NCT03843359 2026-01-08
A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Active not recruiting
NCT05565378 2026-01-08
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
GlaxoSmithKline
Phase 2 Active not recruiting
NCT03955978 2026-01-06
TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
Washington University School of Medicine
Phase 1 Active not recruiting
NCT03602859 2025-12-31
FIRST
Tesaro, Inc.
Phase 3 Active not recruiting
NCT05201547 2025-12-04
DOMENICA
ARCAGY/ GINECO GROUP
Phase 3 Active not recruiting
NCT06640049 2025-11-17
China AZUR-1
GlaxoSmithKline
Phase 2 Active not recruiting
NCT06521567 2025-11-12
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT02817633 2025-10-28
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Tesaro, Inc.
Phase 1 Active not recruiting
NCT04446351 2025-10-27
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Active not recruiting
NCT04139902 2025-10-15
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
University of Pittsburgh
Phase 2 Active not recruiting
NCT04837209 2025-10-01
NADiR
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT04655976 2025-09-26
COSTAR Lung
GlaxoSmithKline
Phase 3 Active not recruiting
NCT06472076 2025-09-10
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
GlaxoSmithKline
Phase 3 Active not recruiting
NCT03981796 2025-09-03
RUBY
Tesaro, Inc.
Phase 3 Active not recruiting
NCT06317311 2025-07-25
RUBY-J
GlaxoSmithKline
Phase 2 Active not recruiting
NCT03833479 2025-05-21
ATOMICC
Grupo Español de Investigación en Cáncer de Ovario
Phase 2 Active not recruiting
NCT05060432 2024-06-21
TIG-006
iTeos Therapeutics
Phase 1/2 Active not recruiting